High incidence of the hepatitis C virus recombinant 2k/1b in Georgia: Recommendations for testing and treatment

Hepatology Research

Volumn 45, Issue 13, 2015, Pages 1292-1298

  Karchava, Marine ^a   Waldenström, Jesper ^d   Parker, Monica ^c   Hallack, Renee ^c   Sharvadze, Lali ^a,b   Gatserelia, Lana ^a   Chkhartishvili, Nikoloz ^a   Dvali, Natia ^a   Dzigua, Lela ^a   Dolmazashvili, Ekaterine ^a   Norder, Helene ^d   Tsertsvadze, Tengiz ^a,b  

^a AIDS and Clinical Immunology Research Center   (Georgia)

^b TBILISI STATE UNIVERSITY   (Georgia)

^c WADSWORTH CENTER   (United States)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Hepatitis C virus sequence; Hybrid virus; Interferon treatment; Phylogenetic analysis

Indexed keywords

NONSTRUCTURAL PROTEIN 5B; PEGINTERFERON; RIBAVIRIN;

ARTICLE; CONTROLLED STUDY; FEMALE; GEORGIA (REPUBLIC); HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 19; HEPATITIS C VIRUS GENOTYPE 1B; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 21; HEPATITIS C VIRUS GENOTYPE 3; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PHYLOGENY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; VIRUS GENOME; VIRUS STRAIN;

EID: 84941878614     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12505     Document Type: Article

References (33)

1. World Health Organization. Hepatitis C fact sheet. 2013. Available at: http://www.who.int/mediacentre/factsheets/fs164/en/ Accessed April 2014.
2. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001; 345: 41-52.
3. Lawitz E, Lalezari JP, Hassanein T et al. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis 2013; 13: 401-8.
4. Lawitz E, Gane EJ. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 369: 678-9.
5. EASL Recommendations on Treatment of Hepatitis C 2014. J Hepatol 2014; 61: 373-95.
6. Ferenci P. Predictors of response to therapy for chronic hepatitis C. Semin Liver Dis 2004; 24 (Suppl 2): 25-31.
7. Zeuzem S. Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well? Ann Intern Med 2004; 140: 370-81.
8. Kalinina O, Norder H, Mukomolov S, Magnius LO. A natural intergenotypic recombinant of hepatitis C virus identified in St. Petersburg. J Virol 2002; 76: 4034-43.
9. Kageyama S, Agdamag DM, Alesna ET et al. A natural inter-genotypic (2b/1b) recombinant of hepatitis C virus in the Philippines. J Med Virol 2006; 78: 1423-8.
10. Moreau I, Hegarty S, Levis J et al. Serendipitous identification of natural intergenotypic recombinants of hepatitis C in Ireland. Virol J 2006; 3: 95.
11. Legrand-Abravanel F, Claudinon J, Nicot F et al. New natural intergenotypic (2/5) recombinant of hepatitis C virus. J Virol 2007; 81: 4357-62.
12. Noppornpanth S, Lien TX, Poovorawan Y, Smits SL, Osterhaus AD, Haagmans BL. Identification of a naturally occurring recombinant genotype 2/6 hepatitis C virus. J Virol 2006; 80: 7569-77.
13. Tallo T, Norder H, Tefanova V et al. Genetic characterization of hepatitis C virus strains in Estonia: fluctuations in the predominating subtype with time. J Med Virol 2007; 79: 374-82.
14. Kurbanov F, Tanaka Y, Avazova D et al. Detection of hepatitis C virus natural recombinant RF1_2k/1b strain among intravenous drug users in Uzbekistan. Hepatol Res. 2008; 38: 457-64.
15. Demetriou VL, Kyriakou E, Kostrikis LG. Near-full genome characterisation of two natural intergenotypic 2k/1b recombinant hepatitis C virus isolates. Adv Virol 2011; 2011: 710438.
16. Ramiere C, Tremeaux P, Caporossi A et al. Recent evidence of underestimated circulation of hepatitis C virus intergenotypic recombinant strain RF2k/1b in the Rhone-Alpes region, France, January to August 2014: implications for antiviral treatment. Euro Surveill 2014; 19 (43): pii: 20944.
17. Morel V, Descamps V, Francois C et al. Emergence of a genomic variant of the recombinant 2k/1b strain during a mixed Hepatitis C infection: a case report. J Clin Virol 2010; 47: 382-6.
18. Sharvadze L, Nelson KE, Imnadze P, Karchava M, Tsertsvadze T. Prevalence of HCV and genotypes distribution in general population of Georgia. Georgian Med News 2008; (165): 71-7.
19. Kurbanov F, Tanaka Y, Chub E et al. Molecular epidemiology and interferon susceptibility of the natural recombinant hepatitis C virus strain RF1_2k/1b. J Infect Dis 2008; 198: 1448-56.
20. Enomoto N, Sakuma I, Asahina Y et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 1996; 334: 77-81.
21. El-Shamy A, Nagano-Fujii M, Sasase N, Imoto S, Kim SR, Hotta H. Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon/ribavirin combination therapy. Hepatology 2008; 48: 38-47.
22. Raghwani J, Thomas XV, Koekkoek SM et al. Origin and evolution of the unique hepatitis C virus circulating recombinant form 2k/1b. J Virol 2012; 86: 2212-20.
23. Newman RM, Kuntzen T, Weiner B et al. Whole genome pyrosequencing of rare hepatitis C virus genotypes enhances subtype classification and identification of naturally occurring drug resistance variants. J Infect Dis 2013; 208: 17-31.
24. Hall TA. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 98/98/NT. Nucleic Acids Symp Ser 1999; 31: 95-8.
25. Tamura K, Stecher G, Peterson D, Filipski A, Kumar S. MEGA6: Molecular Evolutionary Genetics Analysis version 6.0. Mol Biol Evol 2013; 30: 2725-9.
26. Viazov S, Ross SS, Kyuregyan KK et al. Hepatitis C virus recombinants are rare even among intravenous drug users. J Med Virol 2010; 82: 232-8.
27. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65.
28. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
29. Hadziyannis SJ, Sette H Jr, Morgan TR et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-55.
30. Hedskog C, Doehle B, Chodavarapu K et al. Characterization of hepatitis C virus inter-genotypic recombinant strains and associated virologic response to sofosbuvir/ribavirin. Hepatology 2014; 46: 471-80.
31. Verbeeck J, Stanley MJ, Shieh J et al. Evaluation of Versant hepatitis C virus genotype assay (LiPA) 2.0. J Clin Microbiol 2008; 46: 1901-6.
32. Bouchardeau F, Cantaloube JF, Chevaliez S et al. Improvement of hepatitis C virus (HCV) genotype determination with the new version of the INNO-LiPA HCV assay. J Clin Microbiol 2007; 45: 1140-5.
33. Morel V, Fournier C, Francois C et al. Genetic recombination of the hepatitis C virus: clinical implications. J Viral Hepat 2011; 18: 77-83.